English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

1. BoffitoM,KurowskiM,KruseGet al. Atazanavir enhancessaquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291–7. 2. BoffitoM,MaitlandD,SamarasingheYetal. Thepharmacokineticsof HIV protease inhibitor combinations. Curr Opin infect Dis 2005; 18: 1–7. 3. Peytavin G, Dominguez S, Lamotte C et al. Minimization of the triple reciprocal lopinavir/ritonavir/amprenavir (LPV/RTV/APV) interaction by low-dose fluconazole (FCZ) in experienced HIV-1-infected patients (Pts) in the Lopigen Prospective Study. In: Abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003. Abstract 864. Antivir Ther 2003; 8 Suppl 1: S428. 4. Koks CH, Crommentuyn KM, Hoetelmans RM et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1infected individuals. Br J Clin Pharmacol 2001; 51: 631–5. 5. Van Heeswijk R, Sabo JP, MacGregor TR et al. The effect of tipranavir/ritonavir 500/200 mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volounteers. In: Abstracts of the Fifth International Workshop on Clinical Pharmacology in HIV Therapy, Rome, 2004. Abstract 20, poster 4.8. 6. Jackson KA, Rosenbaum SE, Kerr BM et al. A population pharmacokineticanalysisofnelfinavirmesylate inhuman immunodeficiencyvirusinfected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000; 44: 1832–7. 7. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32: 1462–7. 8. NiwaT,ShiragaT,TakagiA.Effect of antifungaldrugsoncytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005; 28: 1805–8.

Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects